Overview

A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

Status:
Unknown status

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction ( a measure of brain shrinkage) and by clinical assessment scores to evaluate disease progression.

Phase:

Phase 2

Details

Lead Sponsor:

Multiple Sclerosis Institute

Treatments:

Interferon beta-1a
Topiramate